Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BIVI with free AI briefings, catalyst countdowns, and dilution alerts.

BIVI · BIOVIE INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$7.7M Cash on Hand
6.6mo Cash Runway
Follow BIVI by email Get an email when BIVI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BIVI, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Bezisterim Alzheimer Disease Phase 3 · NCT04669028 Completed
BIV201 continuous infusion Ascites Phase 2 · NCT04112199 Terminated

Also used in these trials (approved or third-party drugs, not BIVI's own candidates): Terlipressin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BIVI holds $7.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.5M/quarter from operations, an estimated runway of 6.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 74 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BIVI files for a raise →

👥 Who Owns BIVI

Insiders 1.8% Other 5%+ holders 6.4% Institutions 36.8% Public and other holders 55%
HolderTypeShares% of sharesAs of
TERREN S. PEIZER Institution (13G, 5%+) 3,050,394 28.44% 2025-06-25
Morgan Stanley Institution (13G, 5%+) 896,822 8.36% 2026-07-31
Alta Partners LLC 5%+ holder (13G) 687,321 6.41% 2026-08-12
Steve Gorlin
Director
Insider 46,358 0.43% 2023-11-09
Robert J Hariri
Director · +71,615 options
Insider 42,254 0.39% 2023-11-09
Richard J Berman
Director · +23,155 options
Insider 40,643 0.38% 2024-11-20
Sigmund Rogich
Director · +163,170 options
Insider 36,926 0.34% 2024-11-20
Cuong V Do
President & CEO, Director · +1.01M options
Insider 18,617 0.17% 2026-11-13
Joseph M Palumbo
Chief Medical Officer · +303,417 options
Insider 6,036 0.06% 2026-08-28
Joanne Wendy Kim
Chief Financial Officer · +223,517 options
Insider 3,441 0.03% 2026-08-28
Amy Suzon Chappell
Director · +57,500 options
Insider 727 0.01% 2026-08-28

Share count 10,724,724 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BIVI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BIVI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.